Clinical Trials Directory

Trials / Conditions / PIK3CA Mutation

PIK3CA Mutation

7 registered clinical trials studyying PIK3CA Mutation — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322
Regor Pharmaceuticals Inc.Phase 1
RecruitingPhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met
NCT06982521
Relay Therapeutics, Inc.Phase 3
RecruitingA Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Over
NCT06789913
Relay Therapeutics, Inc.Phase 2
CompletedFirst-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT05759949
Relay Therapeutics, Inc.Phase 1
WithdrawnAlpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcino
NCT05472220
Pamela MunsterPhase 1
CompletedCombination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanc
NCT05300048
Faeth TherapeuticsPhase 1
RecruitingFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance
NCT05216432
Relay Therapeutics, Inc.Phase 1